Nanomedicine (London, England) · 2023
Exploring state-of-the-art advances in targeted nanomedicines for managing acute and chronic inflammatory lung diseases.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maurya Sujata, Srivastava Rashi, Arfin Saniya, Hawthorne Susan, Jha Niraj Kumar, Agrawal Kirti, Raj Sibi, Rathi Brijesh, Kumar Arun, Raj Riya, Agrawal Sharad, Paiva-Santos Ana Cláudia, Malik Asrar Ahmad, Dua Kamal, Rana Rakesh, Ojha Shreesh, Jha Saurabh Kumar, Sharma Ankur, Kumar Dhruv, El-Zahaby Sally A, Nagar Amka
Аннотация
Diagnosis and treatment of lung diseases pose serious challenges. Currently, diagnostic as well as therapeutic methods show poor efficacy toward drug-resistant bacterial infections, while chemotherapy causes toxicity and nonspecific delivery of drugs. Advanced treatment methods that cure lung-related diseases, by enabling drug bioavailability via nasal passages during mucosal formation, which interferes with drug penetration to targeted sites, are in demand. Nanotechnology confers several advantages. Currently, different nanoparticles, or their combinations, are being used to enhance targeted drug delivery. Nanomedicine, a combination of nanoparticles and therapeutic agents, that delivers drugs to targeted sites increases the bioavailability of drugs at these sites. Thus, nanotechnology is superior to conventional chemotherapeutic strategies. Here, the authors review the latest advancements in nanomedicine-based drug-delivery methods for managing acute and chronic inflammatory lung diseases.